Independence is constantly evaluating our policies and industry trends to identify opportunities to make specialty drugs more affordable without limiting members' access to life-saving medications. As a result, Independence has changed how we manage the colony-stimulating factors (CSFs) drug class.
As of April 1, 2021, Independence designated the following CSF drugs as preferred products:
- Long-acting CSFs
- Fulphila® (pegfilgrastim-jmdb)
- Neulasta® (pegfilgrastim)
- Udenyca® (pegfilgrastim-cbqv)
- Short-acting CSFs
- Granix® (tbo-filgrastim)
- Zarxio® (filgrastim-sndz)
To learn more about these changes and policy updates, please read our announcement article.